NasdaqCM - Nasdaq Real Time Price USD

Galmed Pharmaceuticals Ltd. (GLMD)

0.3835 -0.0046 (-1.19%)
As of 2:44 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
7,492.0000
7,492.0000
17,651.0000
32,881.0000
30,210.0000
Operating Income
-7,492.0000
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
Net Non Operating Interest Income Expense
364.0000
364.0000
275.0000
519.0000
1,161.0000
Other Income Expense
216.0000
216.0000
-490.0000
-105.0000
278.0000
Pretax Income
-6,912.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Net Income Common Stockholders
-6,912.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Diluted NI Available to Com Stockholders
-6,912.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Basic EPS
-2.50
--
-10.65
-19.80
-20.25
Diluted EPS
-2.50
--
-10.65
-19.80
-20.25
Basic Average Shares
2,769.5390
--
1,676.1830
1,639.8430
1,418.7190
Diluted Average Shares
2,769.5390
--
1,676.1830
1,639.8430
1,418.7190
Total Operating Income as Reported
-7,492.0000
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
Rent Expense Supplemental
261.0000
261.0000
401.0000
530.0000
430.0000
Total Expenses
7,492.0000
7,492.0000
17,651.0000
32,881.0000
30,210.0000
Net Income from Continuing & Discontinued Operation
-6,912.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Normalized Income
-7,128.0000
-7,128.0000
-17,376.0000
-32,362.0000
-29,049.0000
Interest Income
375.0000
375.0000
297.0000
562.0000
1,192.0000
Net Interest Income
364.0000
364.0000
275.0000
519.0000
1,161.0000
EBIT
-7,492.0000
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
EBITDA
-7,461.0000
-7,461.0000
-17,616.0000
-32,839.0000
-30,171.0000
Reconciled Depreciation
31.0000
31.0000
35.0000
42.0000
39.0000
Net Income from Continuing Operation Net Minority Interest
-6,912.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Total Unusual Items Excluding Goodwill
216.0000
216.0000
-490.0000
-105.0000
278.0000
Total Unusual Items
216.0000
216.0000
-490.0000
-105.0000
278.0000
Normalized EBITDA
-7,677.0000
-7,677.0000
-17,126.0000
-32,734.0000
-30,449.0000
12/31/2020 - 3/13/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.8295
+2.21%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.0512
-0.29%
 
DRMA Dermata Therapeutics, Inc.
0.3500
-1.69%
 
GALT Galectin Therapeutics Inc.
3.4700
-0.86%
 
CNTB Connect Biopharma Holdings Limited
1.3100
-2.96%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
KZR Kezar Life Sciences, Inc.
0.8025
+1.58%
 
APTO Aptose Biosciences Inc.
1.2399
+6.89%
 
IMRN Immuron Limited
2.6300
+5.62%